DataMeds AI cuts staff, refocuses on ChemoFx cancer diagnostic test

Go back to DataMeds AI cuts staff, refocuses on ChemoFx cancer diagnostic test

DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division

October 13, 2026 6:01 AM EDT

TAMPA, FL / ACCESS Newswire / October 13, 2026 / DataMeds AI, Inc. (NASDAQ: MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx and smart contracts platform PharmacyChain, today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx® as a diagnostic lab test to help... More